We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Diabetes Can Be Controlled in Patients After Pancreas Removal

By HospiMedica International staff writers
Posted on 19 Sep 2012
A new study suggests that removing the entire pancreas in patients with cancer or precancerous cysts does not result in unmanageable diabetes.

Research at the Mayo Clinic (Jacksonville, FL, USA) conducted a retrospective study involving 14 patients who underwent total pancreatectomy (TP); Hemoglobin A1C (HbA1C) was measured at 6, 12, 18, and 24 months after TP. More...
The researchers then compared their findings with 100 people with type 1 diabetes mellitus (DM) who need to use insulin replacement; baseline measurement in the control group was defined as 6 months prior to the first HbA1c measure.

They researchers found the mean HgbA1C at each point of interest was similar between the TP and type I DM patient cohort. Seven TP patients (50%) experienced a hypoglycemic event compared to 65 type 1 DM patients (65%). Both groups had little difficulty controlling their blood sugar, and no complications resulted. According to the researchers, the findings suggest that glycemic control following TP can be well managed. The study was published early online on August 26, 2012, in HPB Surgery.

"What we have shown here is that, due to wonderful recent improvements in insulin therapy, patients without a pancreas can control their blood sugar as effectively as type 1 diabetes patients can,” said senior investigator Michael Wallace, MD, chair of the division of gastroenterology and hepatology. “Most surgeons today make difficult decisions about how much of the pancreas to remove in a patient, but that process may become a little more straightforward now that we have demonstrated patients do well when their entire pancreas is removed.”

Even though the approach of preserving as much of the pancreas as possible benefits most patients, leaving part of the pancreas in others may put them at risk of developing hard-to-detect cancer in the remaining organ. Similarly, patients who have a potentially precancerous cystic condition known as intraductal papillary mucinous neoplasm in part of the pancreas can develop the same cysts in the part of the pancreas that remains after partial removal. Removing the entire pancreas eliminates the possibility of recurrence in the residual pancreas.

Related Links:
Mayo Clinic



Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
X-Ray Generator
Advantage Plus Generators
Medical Examination & Procedure Light
Vega 80
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.